Asia now generates 43% of the world’s innovative biopharma pipeline, up from 28% five years ago, with China driving more than 85% of 2024’s global pipeline growth alone.
Asia has become the epicenter of global biopharmaceutical progress, outpacing the United States and Europe on pipeline growth, patents, and next-generation therapies. In just five years, Asia has expanded its share of the global innovative pipeline from 28% to 43%, surpassing both the US and Europe combined. In 2024 alone, Asia contributed more than 85% of the global growth in innovative drug pipelines, with China and South Korea leading the surge in new clinical assets.
Asia Now Generates Nearly Two-Thirds of Global Biotech Patents
The scale of the shift shows up across multiple innovation metrics. In 2024, Asia generated nearly two-thirds of global biotech patent grants — five times Europe’s share — and contributed about a quarter of global out-licensing deals. Asia still accounts for only around one in ten FDA novel-drug approvals, a lagging indicator the research expects to catch up as the region’s earlier-stage gains mature into approvals.
China Is the Pacesetter: 29-30% of the Global Pipeline, and Accelerating
Within Asia, China stands out as the clear pacesetter, representing 29-30% of the global innovative pipeline and cutting development timelines far below industry averages. China raised $26 billion in private equity and venture capital between 2019 and 2024, and more than 80 Chinese biopharma companies went public in that period. Early discovery-to-IND (investigational new drug) cycles in China run 50-70% faster than the rest of the world, thanks to parallelized workflows, dense contract research ecosystems, and executional intensity. In late development, trial recruitment often runs two to five times faster than US and EU benchmarks. China’s share of global clinical trials reached 39% in 2023.
Regulatory reform has compressed China’s approval timelines dramatically: the country’s accession to the International Council for Harmonisation (ICH), combined with a fourfold increase in staffing at its drug evaluation center, cut approval duration from 4.5 years in 2018 to about one year by 2023. Upfront payments from China-originated out-licensing deals grew from below $100 million in 2020 to more than $800 million in 2024.
South Korea: Multibillion-Dollar Licensing Deals in Advanced Biologics
South Korea has built particular strength in antibody-drug conjugates and cell and gene therapies, landing headline licensing deals including GSK’s $2.5 billion agreement with ABL Bio for blood-brain-barrier-crossing neurodegenerative drugs and LigaChem’s $1.7 billion partnership with J&J Innovative Medicine. Biopharma is now one of 55 “National Strategic Technologies” designated by the South Korean government, and the Korea Drug Development Fund has committed $2 billion to support more than 1,200 innovation projects through 2030. Roughly 40 biotech IPOs have launched on the KOSDAQ exchange since 2018, including pre-revenue companies.
Japan: Fewer IPOs, More Global Franchises
Japan leads the region in FDA novel-drug approvals, with 24 new molecular entities approved between 2015 and 2023, built on global franchises like Daiichi Sankyo in antibody-drug conjugates and Eisai in Alzheimer’s disease. Japan’s AMED research agency operates on an annual budget of approximately $1 billion across six core research pillars, and one in four leaders at Japan’s top pharma companies has international work experience.
Singapore: Southeast Asia’s Early-Stage Innovation Hub
Singapore has positioned itself as Southeast Asia’s leading hub for early-stage biopharma, anchored by institutions like Biopolis and A*STAR. Since 2010, the Singaporean government has committed more than $45 billion through its Research, Innovation, and Enterprise programs — $27 billion from 2010-2020 and $19 billion from 2021-2025 — with roughly half allocated to biomedical and health sciences. Singapore’s R&D investment, at just under 2% of GDP, still trails Japan and South Korea but outpaces most regional peers.
India’s Innovation Pipeline Grew 1.5x — From 270 to 450 Assets — in a Decade
India is evolving from a generics leader into a more diversified biopharma hub. The country leads the world in pharmaceutical manufacturing scale, with more than 750 FDA-approved facilities and more than 2,050 facilities certified by the World Health Organization for good manufacturing practices. Indian firms are expanding beyond generics into biosimilars, injectables, and antibody-drug conjugates, with more than 138 biosimilars now approved across all markets. India’s own innovation pipeline expanded from roughly 270 assets in 2015 to about 450 in 2024 — a 1.5x rise.
In 2023, the Indian government launched a national policy to boost pharma and medtech R&D, backed by $600 million through a Research-Linked Incentive program running until 2028. Private capital is following: between $2.5 billion and $3 billion was invested in pharmaceutical R&D in fiscal year 2024, while total private equity and venture capital investment in India grew 9% year over year to about $43 billion, with healthcare and biopharma taking a growing share. India also supports more than 1,000 biotech start-ups and 12 biotech parks.
Four Playbooks Asian Biopharma Firms Use to Go Global
The research identifies four business models Asian biopharma companies use to commercialize innovation internationally. Out-licensing — developing a drug candidate domestically, then licensing rights to a foreign partner for development and launch — remains the mainstay, accounting for around 25% of global out-licensing deals from Asia. Strategic partnerships involve co-developing and co-commercializing products, sharing costs and revenue, and account for roughly 30% of global partnerships. Direct-to-global sees companies independently enter international markets without a partner — Japan’s Takeda and Eisai, and China’s BeOne, are cited examples. The newest model, NewCo, involves spinning off pipeline assets into a newly formed foreign entity with its own investors and local leadership; more than ten such deals have closed in the past year, with China accounting for most of that activity.
Why This Matters for Global Investors
The research frames Asia’s rise as a strategic imperative rather than a regional curiosity. Multinational investors “can no longer afford to overlook Asia,” the analysis argues, warning that “investors who sat out the last cycle risk missing the next one.” AstraZeneca’s 2024 acquisition of Gracell Biotechnologies, a China-founded cell-therapy company, is cited as an early example of Asia-origin innovation entering global pipelines. The report also points to a distinct cost advantage: Chinese biopharma firms reportedly run discovery programs at roughly one-third to one-half of global costs, and clinical development at 20-50% of US levels — positioning Asia, and China specifically, to potentially lead in affordable, scalable innovation for underserved patient populations across the Global South.